AIDA MEETING ROOM | FLOOR -1
10.30 AM WELCOME – OPENING CEREMONY
Chairs: Emanuel Della Torre, John H. Stone, Yoshiya Tanaka
10.35 AM Unmet needs and open research fields in IgG4-related disease – Emanuel Della Torre
10.50 AM IgG4-related disease: Twenty years from discovery to IgG4ward! – John H. Stone
11.10 AM What’s New (WIN) for PATIENTS
Presentation of the European Reference Network Working Group on IgG4-related disease – Tobias Alexander
11.30 AM Patient experience and PROMs definition: a round table with ERN-ReConnet and IgG4ward! ePAG representatives – Ilaria Galetti
12.30 PM INDUSTRY SYMPOSIUM – NO ECM
With the unrestricted support of AMGEN
Defining IgG4-related disease activity. Where do we stand and where are we going – Marco Lanzillotta, Giuseppe Alvise Ramirez
01.00 PM BUFFET LUNCH

WHAT’S NEW IN THE PATHOGENESIS OF IgG4-RELATED DISEASE – PART I
Chairs: Shiv Pillai, Cory Perugino
02.00 PM Overview of IgG4RD pathogenesis – Cory Perugino
02.20 PM Updates on the role of Th / Tfh cells in the pathogenesis of IgG4-related disease – Shingo Nakayamada
02.40 PM Single cell interrogation of T-lymphocytes infiltrating IgG4-related disease affected tissues: a novel perspective into the pathogenesis of IgG4-related disease – Takashi Maehara
03.00 PM Unusual B-lymphocytes subsets in the pathogenesis of IgG4-related disease: is there a role for “double negative” B-cells? – Hugues Allard-Chamard
03.20 PM Single cell interrogation of B-lymphocytes infiltrating IgG4-related disease affected tissues: a novel perspective into the pathogenesis of IgG4-related disease – Cai Shaozhe
03.40 PM From Fab-arm exchange to glycosylation: unique properties of IgG4 antibodies in the pathogenesis of IgG4-related disease and in vivo models to study them – Teo Riespens
04.00 PM Controversies around the complement system in the pathogenesis of IgG4-related disease – Guy Katz
04.30 PM COFFEE BREAK

WHAT’S NEW IN THE PATHOGENESIS OF IgG4-RELATED DISEASE – PART II
Chairs: Hugues Allard-Chamard, Takashi Maehara
05.00 PM SELECTED ABSTRACTS – NO ECM
• IL-21/STAT3 pathway mediated Th2-like Vδ2 T cells promote plasmablasts differentiation in IgG4-Related
Disease Jieqiong Li (China)
• Anti-fibroblast autoantibodies in IgG4-RD patients. Federico Pratesi (Italy)
• Flow cytometry of intestinal microbiota identifies a phenotypic imprint on a single cell level in IgG4-related
disease Anne Beenken (Germany)
• Association of IgG4-related disease with an immunologic response to cancer Claudia Minici (Italy)
Chair: Shiv Pillai
06.00 PM LECTURE: T-follicular regulatory cells at the cross-road between autoimmunity and allergy. To IgG4 production and beyond -Carola Vinuesa
06.30-08.30 PM
POSTER SESSION “WINE and CHEESE”
FONTANA Meeting room – Floor 0

AIDA MEETING ROOM | FLOOR -1
WHAT’S NEW IN THE EPIDEMIOLOGY OF IgG4-RELATED DISEASE
Chairs: Ulrich Beuers, Zachary Wallace
08.00 AM LECTURE: Sex-related immunological differences in autoimmunity: where does IgG4-related disease stand? – Coziana Ciurtin
08.30 AM The changing epidemiology of IgG4-related disease. What we learned in the last 20 years – Zachary Wallace
08.50 AM SELECTED ABSTRACT – NO ECM
• Pediatric and Adult Perspectives of Immunoglobulin G4-Related Disease: Results of a multicentric registry
Mustafa Ekici (Turkey)
09.00 AM Genetic susceptibility of IgG4-related disease Emanuel Della Torre
09.20 AM SELECTED ABSTRACT – NO ECM

• Genome-Wide Association Studies Reveal New Insights into the Genetic Basis of IgG4-Related Disease in the Chinese Han Population Songxin Yan (China)
09.30 AM INDUSTRY SYMPOSIUM NO ECM
With the unrestricted support of ZENAS
The critical role of accurate diagnosis of IgG4-RD: a multidisciplinary approach
An Interdisciplinary Approach to IgG4-Related Disease – Mollie Carruthers
Deciphering the IgG4-RD conundrum and its mimics: Clinical and Diagnostic perspectives – Andrés González
10.30 AM COFFEE BREAK
CLINICAL MANIFESTATIONS OF IgG4-RELATED DISEASE: “ANOTHER GREAT MIMICKER” – PART I
UEG/EPC/EASL JOINT SESSION
Chairs: Matthias Lohr, Luca Frulloni, Gabriele Capurso, Pietro Invernizzi
11.00 AM Differentiating type 1 and type 2 autoimmune pancreatitis: diagnostic and clinical implications – Matthias Lohr

11.20 AM IgG4-related cholangitis and hepatitis: controversies in the diagnosis and management – Ulrich Beuers
11.40 AM Inflammatory Bowel “IgG4-related disease”: myth or reality? – Ferdinando D’Amico
12.00 PM Role of endoscopy for biliary tree and pancreatic involvement of IgG4-related disease: a practical appraisal – Mariana Arvanitaki
12.20 PM Post-surgery outcomes of pancreato-biliary IgG4-related disease – Miroslav Vujasinovic
12.40 PM Organ damage in IgG4-related disease and management of secondary comorbidities – Emma Culver
01.00 PM BUFFET LUNCH
CLINICAL MANIFESTATIONS OF IgG4-RELATED DISEASE: “ANOTHER GREAT MIMICKER” – PART II
Chairs: Mikael Ebbo, Mitsuhiro Kawano
02.00 PM Differentiating “fibrotic” and “lymphoproliferative” IgG4-related disease: why it matters – Wen Zhang
02.20 PM Primary and secondary IgG4-related disease – Nicholas Schleinitz
02.40 PM IgG4-related disease as a novel form of systemic vasculitis J- ames Stone
03.00 PM Retroperitoneal fibrosis: when is IgG4-related and when is not – Augusto Vaglio
03.20 PM Renal involvement of IgG4-related disease – Giacomo Quattrocchio
03.40 PM Salivary gland involvement of IgG4-related disease: the role of salivary gland biopsy and ultrasound in the diagnostic process – Masafumi Moriyama
04.00 PM Lymph-node involvement of IgG4-related disease: how to extricate in the differential diagnosis – Luke Chen

WHAT’S NEW IN THE DIAGNOSIS OF IGG4-RELATED DISEASE – PART I – HOW TO ACHIEVE A CORRECT DIAGNOSIS
Chairs: Fernando Martinez Valle, Tobias Alexander
08.00 AM Pathology of IgG4-related disease (when IgG4-related disease is not IgG4-related disease) – Yoh Zen
08.20 AM Update on available biomarkers of IgG4-related disease – Marco Lanzillotta
08.40 AM Distinguishing active/fibrotic IgG4-related disease. The role of 18FDG-PET and new tracers – Andreas Ramming
09.00 AM How to image active and fibrotic IgG4-related disease – Diego Palumbo
09.20 AM IgG4-related disease clinical phenotypes and their impact on patient management – Andreu Fernandez-Codina
09.40 AM Clinical utility of the 2019 ACR/EULAR classification criteria for IgG4-related disease 5 years down the road – Vinciane Rebours
10.00 AM COFFEE BREAK
WHAT’S NEW IN THE DIAGNOSIS OF IGG4-RELATED DISEASE – PART II – OVERLOOKED DIFFERENTIAL DIAGNOSIS
Chairs: Nicholas Schleinitz, Marco Matucci Cerinic
10.30 AM Castleman’s Disease – Éric Oksenhendler
10.50 AM Autoimmune lymphoproliferative disease – Frederic Rieux-Laucat
11.10 AM Systemic Histiocytoses – Lorenzo Dagna
11.30 AM Mesenchymal tumors and sclerosing mesenteritis – Alessandro Gronchi
12.00 PM BUFFET LUNCH
WHAT’S NEW IN THERAPY OF IGG4-RELATED DISEASE – PART I
CONTROVERSIES in TREATMENT and PROGNOSIS of IgG4-RELATED DISEASE
Chairs: Giacomo Quattrocchio, Ling Li Dong
01.00 PM Current available treatment guidelines for IgG4-related disease: is it time to change? – Fernando Martinez Valle
01.20 PM Glucocorticoids – what the best scheme for induction and maintenance of remission of IgG4-related disease – Yoshiya Tanaka

01.40 PM Is there a time to stop immunosuppressive therapy in patients with IgG4-related disease? – Arezou Khosroshahi
02.00 PM Long-term outcomes of IgG4-related disease: is there an increased risk of solid or hematologic malignancies? – Jan Van Laar
02.20 PM SELECTED ABSTRACTS – NO ECM
• Peripheral blood CD8 effector memory T cells re-expressing CD45RA is a predictor of disease flare in IgG4-related disease Satoshi Kubo (Japan)
• Improved renal function in initial treatment improves patient survival, renal outcomes, and glucocorticoid-related
complications in IgG4-related kidney disease in Japan Ichiro Mizushima (Japan)
• Revealing the distinct clinical patterns and relapse risk factors in seronegative IgG4-RD patients: a retrospective cohort study over a decade Yu Peng (China)
03.00 PM COFFEE BREAK
WHAT’S NEW IN THERAPY OF IgG4-RELATED DISEASE – PART II
Chairs: Wen Zhang, Emma Culver
03.30 PM Is spontaneous remission of IgG4-related disease possible and what does it teach us about disease pathogenesis? – Mitsuhiro Kawano
03.50 PM B-cell depletion in IgG4-related disease: pros and cons from a 10 years experience – Mikael Ebbo
04.10 PM Repurposing biologic agents for treating IgG4-related disease: what can we learn from available case series – Ling Li Dong
04.30 PM SELECTED ABSTRACT – NO ECM
• Successful Treatment of refractory IgG4-Related Disease with Tofacitinib. Experiences From 7 Patients
Huaqun Zhu (China)
04.40 PM Updates from clinical trials in IgG4-related disease – John H. Stone
05.15 PM Conclusive remarks – Emanuel Della Torre